Sorrento Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Operating activities:
Net loss
Public Offering Of Common Stock And Warrants 2019
Total net loss
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization
Non-cash operating lease cost
Non-cash interest expense and amortization of debt issuance costs
Amortization of debt issuance costs and debt discount
Scilex Notes principal increase
Payments on notes attributed to accreted interest related to the debt discounts
Loss on trading securities
Stock-based compensation
Acquired in-process research and development
Loss on disposal for property and equipment
Loss on receivable
(Gain) loss on debt extinguishment, net
(Gain) loss on derivative liability
Loss on marketable and equity investments
Loss on equity method investments
Non-cash income on cost method investments
Loss (gain) on contingent liabilities
Loss on impairment of intangible assets
(Gain) loss on contingent consideration
Non-cash inventory adjustments
Deferred income taxes
Loss on IPR&D impairment
Changes in operating assets and liabilities, excluding effect of acquisitions:
Accounts receivable
Inventory
Accrued payroll
Prepaid expenses, deposits and other assets
Deposits and other assets
Accounts payable
Accrued legal settlements
Accrued expenses and other liabilities
Deferred revenue
Acquisition consideration payable
ACEA Therapeutics, Inc
Total acquisition consideration payable

Other

Net cash used for operating activities
Investing activities:
Proceeds from sale of marketable investments
Purchases of property and equipment
Purchase of assets related to Sofusa
Payments to Investments
Purchase of assets related to Semnur, net of cash acquired
Payments related to license agreements
Acquisition consideration paid in cash, net of cash acquired
Virex Health, Inc
ACEA Therapeutics, Inc
Other Acquisitions and Investments
Total acquisition consideration paid in cash, net of cash acquired
Net cash provided by (used for) investing activities

Financing activities:
Net borrowings under loan and security agreement
Payments on short term bridge loan
Milestones Achievement
Total payments on short term bridge loan
Proceeds from issuance of common stock
Public Offering Of Common Stock And Warrants 2019
ATM Facility
Distribution Agreement
Total proceeds from issuance of common stock

Proceeds from exercises of stock options and warrants
Payments on bridge loans and Scilex Notes
Proceeds from 2017 Securities Purchase Agreement, net of issuance costs
Proceeds from issuance of Scilex notes, net of issuance costs
Scilex notes issuance of Scilex notes
Oaktree Term Loan
Total scilex notes issuance of Scilex notes
Proceeds from issuance of convertible notes
Cash payments for treasury shares
Proceeds from loan and security agreement, net of fees
Payments of debt on retired note
Payment of Hercules Loan Agreement
Scilex consideration for regulatory milestones
Net payments of deferred compensation
Proceeds from Oaktree Term Loans, net of issuance costs
Oaktree Term Loan
Total proceeds from Oaktree Term Loans, net of issuance costs

Proceeds from short-term debt, net of issuance costs
Milestones Achievement
Total proceeds from short-term debt, net of issuance costs

Repayments of debt and other obligations
Proceeds from Business Combination
Transaction costs paid related to Business Combination
Payments related to Semnur Share Exchange
Net cash provided by financing activities

Net change in cash, cash equivalents and restricted cash
Net effect of exchange rate changes on cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosures:
Cash paid during the period for:
Income taxes
Interest
Supplemental disclosures of non-cash investing and financing activities:
Changes to noncontrolling interests related to Business Combination
Business Combination transaction costs incurred but not paid
Acquisition consideration paid in equity
SmartPharm
Semnur
Virex Health, Inc
Total acquisition consideration paid in equity

Semnur acquisition costs incurred but not paid
Other acquisitions, license agreements and investments paid in equity
Non-cash consideration given
Virttu Biologics Limited
Scilex Pharmaceuticals, Inc
BDL stock issuance
Sini West
Roger Williams Medical Center
BDL
Scilex Pharmaceuticals, Inc
Investment in ImmuneOncia
Scilex Notes principal increase
ACEA acquisition consideration paid in equity
Right-of-use assets obtained in exchange for new and amended operating lease liabilities
Other acquisitions, license agreements and investments consideration paid in equity
Changes to noncontrolling interests from increased ownership in Scilex Holding
Conversion of convertible notes
Other loan forgiveness
Loss on debt extinguishment
June 2018 Warrants, Amendment
Scilex Pharmaceuticals, Inc
Total loss on debt extinguishment

Deferred consideration for intangible asset acquisition
Short-term debt
Property and equipment costs incurred but not paid

Cash and cash equivalents
Restricted cash

Comments